Acute and Chronic Repercussion of Spinal Cord Stimulation After Spinal Cord Injury
Mayo Clinic · NCT07210411
Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.
Key facts
- Compensation
- Not posted. Ask the study team before screening.
- Who can join
- Ages 18–50 · All sexes
- Healthy volunteers
- Accepted
- Study type
- Interventional · Not applicable
- Target enrollment
- 80
- US sites recruiting
- 1
- Study start
- March 5, 2026
- Record last updated
- May 28, 2026
Status re-checked against ClinicalTrials.gov within the last 12 hours.
What the study is about
The purpose of this research is to learn about how the participant's body is able to balance changes in blood pressure, and how spinal cord stimulation affects these changes as well as immune \& cardiovascular function in participants with spinal cord injury.
Being studied: Tests of sympathetic inhibition; Tests of above level sympathetic activation; Testing of below level sympathetic activation; Epidural stimulation; Transcutaneous stimulation
Conditions: Spinal Cord Injuries
Eligibility criteria
Copied from the official record. The study team makes the final decision at screening.
Show full criteria
Inclusion criteria
- Age 18-50.
- American Spinal Injury Association Impairment Scale A-D,64 to encompass a representational spectrum of autonomic dysfunction after spinal cord injury.
- Neurological level of injury, C6-T8, as defined by the International Standards for Neurological Classification of Spinal Cord Injury.64 Incorporating level of injury over this broad range to capture the spectrum of autonomic dysfunction. Individuals with injuries below T8 will not be included to ensure transcutaneous spinal cord stimulation does not occur over the injury/glial scar, where it may have altered properties. The C6 level was chosen to ensure hand cold pressor stimuli triggers above level sympathetic activation.
- Time since injury of greater than six months, given early changes in spinal cord connectivity and recovery prior to this.
- Both individuals with and without currently implanted epidural spinal cord stimulators will be enrolled.
- Twenty uninjured controls will also be enrolled.
Exclusion criteria
- History of clinically diagnosed cardiovascular disease, diabetes, autonomic neuropathies, neurological disorders (with exception of spinal cord injury for individuals in those cohorts), or are active smokers.
- Individuals who are taking betablockers, antihypertensives, or other sympathetically active medications which they are unable to hold.
- Women who are pregnant or lactating, given known hormonal influences on autonomic regulation.65,66
- Cognitive issues preventing informed consent for participation.
- Body mass index >30 kg/m2 for the uninjured controls only given increased risk of prediabetes and potential confounding normative values.
- taking or being administered a medication known to potentially have adverse interactions with phenylephrine
- in the judgement of the principal investigator, any illness or condition that will interfere with the patient's ability to comply with the protocol, compromise patient safety, or interfere with the interpretation of the study results
Recruiting US locations
Mayo Clinic
Rochester, MN 55905
Site contact: Erin Lund · 507-284-9298 · lund.erin@mayo.edu
Study contacts (from the official record)
- Erin Lund · 507-284-9298 · lund.erin@mayo.edu
Similar studies in Minnesota
All healthy volunteers studies in Minnesota →- RecruitingHealthy volunteersPhase 1Overnight stay mentioned
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
Pfizer
- Location
- Saint Paul, MN + 3 other US sites
- Eligibility basics
- Ages 18–80
- RecruitingHealthy volunteersPhase 1/Phase 2
Harmony-HHT: ATV-1601 in Participants With Hereditary Hemorrhagic Telangiectasia (HHT)
Atavistik Bio, Inc
- Location
- Rochester, MN + 5 other US sites
- Eligibility basics
- Ages 18+
- RecruitingHealthy volunteersPhase 1/Phase 2
First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
- Location
- Dilworth, MN + 2 other US sites
- Eligibility basics
- Ages 25–75
- RecruitingHealthy volunteersPhase 1
A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD4248 in Healthy Participants and Participants With Chronic Kidney Disease and Type 2 Diabetes and to Assess Home Measurements of…
AstraZeneca
- Location
- Saint Paul, MN + 3 other US sites
- Eligibility basics
- Ages 18–75